Type Iii Procollagen Peptide: A Marker of Disease Activity and Prognosis in Primary Biliary Cirrhosis

Babbs, Christopher; Hunt, L P; Haboubi, N.Y.; Smith, Alwyn; Rowan, BrendaP.; Warnes, Thomas W.

doi:10.1016/s0140-6736(88)91843-0

Cited by 68 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results indicated that a decrease in vitamin D levels could reflect the severity of hepatocellular injury and so serve as a new hepatic biomarker in progressive liver diseases (El Husseiny et al, 2012; Schaalan et al, 2012). Even so, these findings are consistent with previous results, indicating that vitamin D inadequacy is common in non-cholestatic chronic liver diseases and correlates with disease severity (Babbs et al, 1988;Fisher and Fisher, 2007). In other earlier studies, a deficient vitamin D status was linked to severe fibrosis and low sustained virologic responses (SVR) during interferon (IFN)-g-based therapies (Abu Mouch et al, 2010;Petta et al, 2010).…”

Section: Discussionsupporting

confidence: 85%

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Hammad¹,

Abdelraouf²,

Hassanein

et al. 2013

Journal of Immunotoxicology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects primarily hepatocytes, leads to development of fibrosis and/or cirrhosis of the liver and is a significant factor for developing hepatocellular carcinoma (HCC). Evidence indicates that liver fibrosis contains uncontrolled inflammation as a part of its etiology. Normal cell-mediated immunity plays a central role in the mechanisms involved in viral clearance/persistence in the liver. In this context, cytokines modulate the immune system and exert direct anti-viral activity. To this end, this study investigated potential associations of serum IL-17 and IL-6 with exacerbation of hepatic damage in chronic HCV patients to determine their utility as prognostic markers for potential development of HCC. Chronic HCV-patients were recruited, divided into groups according to degree of liver damage, i.e. patients with perihepatic fibrosis, hepatic cirrhosis, or HCC, and had their blood collected for analysis of liver function and serum IL-6 and IL-17 levels. Interestingly, increases in serum IL-17 levels in the study groups were associated with aggravation of the clinical state from HCV to cirrhosis and then to HCC. Serum IL-6 levels followed a similar pattern. The association of both cytokines with progressive exacerbation of the initial HCV-induced liver damage was further confirmed by correlation analysis that revealed positive correlations between HCV RNA titer and IL-17 (þ0.951, p50.05) and IL-6 (þ0.85, p50.05). A receiver operating characteristics (ROC) analysis revealed their beneficial addition as promising biomarkers for a better prognostic profile of HCC. Interestingly, a significant progressive decline in the active vitamin D status was noted in all three clinical states, and these too were associated with progressive liver disease. This study confirms the necessity of adding screening for IL-6 and IL-17 and vitamin D to that of the classic marker AFP for patients with HCV and cirrhosis to hopefully permit clinicians to initiate measures that ultimately might mitigate/delay development of HCC in these infected patients.

show abstract

Section: Discussionsupporting

confidence: 85%

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Hammad¹,

Abdelraouf²,

Hassanein

et al. 2013

Journal of Immunotoxicology

View full text Add to dashboard Cite

show abstract

“…Hyaluronic acid and type III procollagen peptide were the most studied. [9][10][11] These are components or split products of the extracellular matrix that are released into the systemic circulation. The sensitivity and specificity of these markers for detection of extensive fibrosis do not exceed 60% and 80%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC

et al. 2006

View full text Add to dashboard Cite

Noninvasive measurement of liver stiffness with transient elastography has been recently validated for the evaluation of hepatic fibrosis in chronic hepatitis C. The current study assessed the diagnostic performance of liver stiffness measurement (LSM) for the determination of fibrosis stage in chronic cholestatic diseases. One hundred one patients with primary biliary cirrhosis (PBC, n ‫؍‬ 73) or primary sclerosing cholangitis (PSC, n ‫؍‬ 28) were prospectively enrolled in a multicenter study. All patients underwent liver biopsy (LB) and LSM. Histological and fibrosis stages were assessed on LB by two pathologists. LSM was performed by transient elastography. Efficiency of LSM for the determination of histological and fibrosis stages were determined by a receiver operating characteristics (ROC) curve analysis. Analysis failed in six patients (5.9%) because of unsuitable LB (n ‫؍‬ 4) or LSM (n ‫؍‬ 2). Stiffness values ranged from 2.8 to 69.1 kPa (median, 7.8 kPa). LSM was correlated to both fibrosis (Spearman's ‫؍‬ 0.84, P < .0001) and histological (0.79, P < .0001) stages. These correlations were still found when PBC and PSC patients were analyzed separately. Areas under ROC curves were 0.92 for fibrosis stage (F) >2, 0.95 for F > 3 and 0.96 for F ‫؍‬ 4. Optimal stiffness cutoff values of 7.3, 9.8, and 17.3 kPa showed F > 2, F > 3 and F ‫؍‬ 4, respectively. LSM and serum hyaluronic acid level were independent parameters associated with extensive fibrosis on LB. In conclusion, transient elastography is a simple and reliable noninvasive means for assessing biliary fibrosis. It should be a promising tool to assess antifibrotic therapies in PBC or PSC. (HEPATOLOGY 2006;43:1118-1124

show abstract

“…An increase in the P-III-P directly reflects the multiplication of collagen, thus the serum P-III-P value implies a biochemical marker for fibrosis of internal organs. To date, the serum P-III-P value has been used as a marker for diagnosing and determining the fibrosis in liver disease (10). That value is known to increase in hypertensive ventricular hypertrophy, dilated cardiomyopathy and acute myocardial infarction (up to 4 months) (11)(12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Steroid Therapy for Pacing Failure in a Patient with Chronic Myocarditis

et al. 2004

View full text Add to dashboard Cite

A 66-year-old man had a progressive increase in the pacing threshold over a one-year period, resulting from chronic myocarditis. Following steroid therapy, the pacing threshold decreased and became stabilized, and was accompanied by a decrease in the serum creatine kinase, cardiac myosin light chains and pro-collagen III peptide values, but cardiac function did not improve. Endocardial biopsy showed that there was no progression in the fibrosis. The pacing failure improved, but the cardiac function did not. It was believed that the steroid therapy suppressed the progression of the inflammation and fibrosis caused by the chronic myocarditis.

show abstract

Type Iii Procollagen Peptide: A Marker of Disease Activity and Prognosis in Primary Biliary Cirrhosis

Cited by 68 publications

References 31 publications

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC

Efficacy of Steroid Therapy for Pacing Failure in a Patient with Chronic Myocarditis

Contact Info

Product

Resources

About